INTERVIEW: Novo CEO downplays Afrezza, pins hopes on oral pipeline
This article was originally published in Scrip
Executive Summary
Novo Nordisk appears not to be worried about any market impact from Afrezza, MannKind’s recently approved inhalable insulin. In an exclusive interview in Copenhagen, the Danish company’s leadership told Scrip's sister publication PharmAsia News that it had taken sufficient steps to maintain its stronghold on the global insulin market.